Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus SPORANOX.
FULVICIN P/G 165 vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
165 mg orally once daily.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal